What do systematic reviews say?

Effects of different delivery devices on growth in children with persistent asthma: hydrofluoroalkane‐metered dose inhaler beclomethasone vs beclomethasone

Effects of different delivery devices on growth in children with… showed no clear difference in linear growth velocity (cm/year) compared with chlorofluorocarbon‐metered dose inhaler beclomethasone (low certainty).

• Inhaled corticosteroids in children with persistent asthma: effects of different drugs and delivery devices on growth 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 212 participants
  Low

Effects of different delivery devices on growth in children with persistent asthma: Easyhaler‐budesonide vs Turbuhaler‐budesonide

Effects of different delivery devices on growth in children with… may leads to higher change in height (cm) over a period of time compared with turbuhaler‐budesonide (low certainty).

• Inhaled corticosteroids in children with persistent asthma: effects of different drugs and delivery devices on growth 2019 · Cochrane Headline outcomes only
  MD 0.37 [0.12, 0.62]
  1 study · 229 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• Inhaled steroids with and without regular salmeterol for asthma: serious adverse events 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention showed no clear difference in asthma‐related non‐fatal SAEc (moderate certainty).

• Inhaled steroids with and without regular salmeterol for asthma: serious adverse events 2018 · Cochrane Headline outcomes only
  OR 1.25 [0.72, 2.16]
  8 studies · 8453 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in all‐cause mortality (moderate certainty).

• Inhaled steroids with and without regular salmeterol for asthma: serious adverse events 2018 · Cochrane Headline outcomes only
  OR 0.8 [0.36, 1.78]
  41 studies · 27951 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in all‐cause non‐fatal SAEc (moderate certainty).

• Inhaled steroids with and without regular salmeterol for asthma: serious adverse events 2018 · Cochrane Headline outcomes only
  OR 1.14 [0.97, 1.33]
  41 studies · 27951 participants
  Moderate

Intervention not reported

• Inhaled steroids with and without regular salmeterol for asthma: serious adverse events 2018 · Cochrane Headline outcomes only
  no estimate extracted
  41 studies · 27951 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in asthma‐related non‐fatal SAEc (low certainty).

• Inhaled steroids with and without regular salmeterol for asthma: serious adverse events 2018 · Cochrane Headline outcomes only
  OR 1.15 [0.83, 1.59]
  41 studies · 27951 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• Inhaled steroids with and without regular salmeterol for asthma: serious adverse events 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Inhaled steroids with and without regular salmeterol for asthma: serious adverse events 2018 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 8453 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in all‐cause non‐fatal SAEc (moderate certainty).

• Inhaled steroids with and without regular salmeterol for asthma: serious adverse events 2018 · Cochrane Headline outcomes only
  OR 1.04 [0.73, 1.48]
  8 studies · 8453 participants
  Moderate

Intervention not reported

• Inhaled steroids with and without regular salmeterol for asthma: serious adverse events 2018 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 8453 participants
  Moderate

Once‐daily ICS/LABA combined inhalers vs once‐daily LAMA

It is very uncertain whether once‐daily ICS/LABA combined inhalers changes mortality (all‐cause) compared with once‐daily LAMA (very low certainty).

• Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic… 2018 · Cochrane Headline outcomes only
  OR 0.2 [0.02, 1.73]
  2 studies · 880 participants
  Very low

Once‐daily ICS/LABA combined inhalers vs once‐daily LAMA

It is very uncertain whether once‐daily ICS/LABA combined inhalers changes pneumonia compared with once‐daily LAMA (very low certainty).

• Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic… 2018 · Cochrane Headline outcomes only
  OR 6.12 [0.73, 51.24]
  2 studies · 880 participants
  Very low

Once‐daily ICS/LABA combined inhalers vs once‐daily LAMA

• Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 779 participants
  Very low

Once‐daily ICS/LABA combined inhalers vs once‐daily LAMA

It is very uncertain whether once‐daily ICS/LABA combined inhalers changes hospital admissions (all‐cause) compared with once‐daily LAMA (very low certainty).

• Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic… 2018 · Cochrane Headline outcomes only
  OR 0.96 [0.49, 1.89]
  2 studies · 880 participants
  Very low

Once‐daily ICS/LABA combined inhalers vs once‐daily LAMA

The review found no eligible studies for this question.

• Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Once‐daily ICS/LABA combined inhalers vs once‐daily LAMA

The review found no eligible studies for this question.

• Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention showed no clear difference in BPD at 28 days (low certainty).

• Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight… 2017 · Cochrane Headline outcomes only
  RR 1.14 [0.96, 1.34]
  2 studies · 233 participants
  Low

Intervention not reported

The intervention probably leads to lower ever diagnosed as asthmatic by 7 years of age (moderate certainty).

• Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight… 2017 · Cochrane Headline outcomes only
  RR 0.42 [0.19, 0.94]
  1 study · 48 participants
  Moderate